RE:RE:RE:MD&A I fully understand your point vikingguy, you always want to see a company execute on their business strategies. I feel CRDL has outstanding health experts as part of their firm and board and if they see the opportunity to expedite their clinical trials for acute myocarditis because of COVID thereby reducing the timeline for approvals, it may be the prudent way to go. The last report I read from Robert McWhirter suggested as much.... "Overall, we think that the testing that will be done on #COVID19 will fast forward the opportunity on the heart side. Right now, I have to believe its the path they are going down as we havent heard from CRDL in almost 2 months.